124 related articles for article (PubMed ID: 23666016)
1. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review.
Kim K; Hernlund E; Hernadi Z; Révész J; Pete I; Szánthó A; Bodnar L; Madry R; Timorek-Lemieszczuk A; Bozanovic T; Vasovic S; Tomasevic Z; Zivaljevic M; Pazin V; Minárik T; Garanová H; Helpianska L; Justo N
Int J Gynecol Cancer; 2013 Jun; 23(5):823-32. PubMed ID: 23666016
[TBL] [Abstract][Full Text] [Related]
2. Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review.
Tichopád A; Müllerová J; Jackowska T; Nemes E; Pazdiora P; Sloesen B; Štefkovičová M
Value Health Reg Issues; 2016 Sep; 10():53-60. PubMed ID: 27881278
[TBL] [Abstract][Full Text] [Related]
3. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study.
Delgado-Ortega L; González-Domínguez A; Borrás JM; Oliva-Moreno J; González-Haba E; Menjón S; Pérez P; Vicente D; Cordero L; Jiménez M; Simón S; Hidalgo-Vega Á; Moya-Alarcón C
Eur J Health Econ; 2019 Feb; 20(1):135-147. PubMed ID: 29922900
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs.
Bencina G; Chami N; Hughes R; Weston G; Baxter C; Maciejczyk A; Popovic L; Karamousouli E; Salomonsson S
J Med Econ; 2023; 26(1):254-261. PubMed ID: 36756852
[TBL] [Abstract][Full Text] [Related]
6. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
7. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
8. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and costs of ovarian cancer therapy in Poland--regional approach].
Kozierkiewicz A; Jach R; Basta T; Śliwczyński A; Tomczyk R; Jędrzejczyk T
Ginekol Pol; 2015 Aug; 86(8):582-9. PubMed ID: 26492706
[TBL] [Abstract][Full Text] [Related]
10. Expert panel on practice patterns in the management of cow's milk protein allergy and associated economic burden of disease on health service in Turkey.
Sekerel BE; Seyhun O
J Med Econ; 2017 Sep; 20(9):923-930. PubMed ID: 28602101
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
12. Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
Dottino JA; Cliby WA; Myers ER; Bristow RE; Havrilesky LJ
Gynecol Oncol; 2015 Sep; 138(3):694-9. PubMed ID: 26072441
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
14. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
16. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
[TBL] [Abstract][Full Text] [Related]
17. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
18. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
[TBL] [Abstract][Full Text] [Related]
19. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
